Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 44.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,538 shares of the company's stock after selling 14,659 shares during the period. Corient Private Wealth LLC's holdings in Moderna were worth $771,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new position in Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after purchasing an additional 388 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $59.00.

Remove Ads

Moderna Stock Performance

Shares of NASDAQ:MRNA traded down $1.00 during trading on Friday, hitting $31.12. The company's stock had a trading volume of 5,681,801 shares, compared to its average volume of 6,817,655. The company has a market capitalization of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The stock's 50-day moving average price is $34.72 and its two-hundred day moving average price is $44.38.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.